Get started
Author

G. Gullo

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
2010 · N Walsh, S Kennedy, et al. · British Journal of Cancer · 42
PDF
1939 Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant Doxorubicin: 10-Year follow-up
2015 · G. Murtagh, E. O'Connell, et al. · European Journal of Cancer · 3
5000 ORAL Long-term Outcome of HER2-positive (HER2+) Metastatic Breast Cancer (MBC) Patients (pts) Achieving Durable Complete Remission (DCR) After Trastuzumab (T)-containing Chemotherapy (CT)
2011 · G. Gullo, M. Zuradelli, et al. · European Journal of Cancer · 3
Pelvic varices diagnosed with endorectal surface coil magnetic resonance imaging: case report.
2000 · G Gullo, P D Russ · PubMed · 3
Use and clinical impact of conventional cytotoxic chemotherapy (CTx) subsequent to immunotherapy in metastatic melanoma
2016 · E.R. Malone, M. Maltese, et al. · Annals of Oncology · 2
Abstract P4-07-08: Budesonide and loperamide do not impact the cytotoxicity of neratinib or HER2-directed monoclonal antibodies in HER2+ breast cancer cell lines
2019 · DM Collins, N Gaynor, et al. · Cancer Research · 1
Outcome of an active surveillance programme for patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): Single institution 10-year experience
2018 · C.L. Lee, G. Gullo, et al. · Annals of Oncology · 1
Use of contrast-enhanced Magnetic Resonance Imaging (MRI) to predict pathological response after trastuzumab (T) – based neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer (HER2BrCa)
2018 · C. Flynn, G. Gullo, et al. · European Journal of Cancer · 1
310P Substantial reduction in the percentage of metastatic breast cancer (MBC) which is HER-2 positive (HER-2+) over two decades: Sequential cohort analysis from the 1000 patient HER-2 study
2021 · J.J. Berenguer-Pina, C.M. Quinn, et al. · Annals of Oncology
PDF
Impact of immune-checkpoint inhibitors (ICPIs) as treatment of patients (pts) with metastatic primary uveal melanoma (UM): Results of a single-institution database
2018 · C.L. Lee, G. Gullo, et al. · Annals of Oncology
Abstract P5-20-05: Impact of type of (neo)adjuvant systemic therapy (AdjTx) and total exposure to trastuzumab (TET) on long-term outcome of HER2-positive (HER2+) early stage breast cancer (ESBrCa)
2018 · G Gullo, N Walsh, et al. · Cancer Research
Impact of an active surveillance programme on outcome of patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): results of a single-institution experience
2017 · C.L. Lee, G. Gullo, et al. · Annals of Oncology
PDF
Clinical factors associated with overall survival (OS) for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) treated with HER2-targeting systemic therapy (HER2Tx)
2017 · G. Gullo, N. Walsh, et al. · European Journal of Cancer
Abstract P1-07-09: Retrospective cohort study of patients (pts) diagnosed with breast cancer (BC) <40 yrs: 2000 to 2015⟨
2016 · M Greally, J Kielty, et al. · Cancer Research
Abstract P4-12-01: Long term follow up of patients (pts) with HER2positive (H+) early stage breast cancer (ESBC) treated with trastuzumab (T)
2016 · R Bose, D Zanoni, et al. · Cancer Research
1879 Impact of adjuvant trastuzumab (adjT) for early-stage (ES) breast cancer (BC) on clinical characteristics, survival and likelihood of durable complete response (DCR) of HER2-positive (HER2+) metastatic breast cancer (MBC): A 15-year single-institution cohort study
2015 · A. Zacchia, G. Gullo, et al. · European Journal of Cancer
Predicting response – The use of neoadjuvant chemotherapy in breast cancer a 5 year review
2012 · Eamon Francis, Aoife Lowery, et al. · International Journal of Surgery
P1-12-22: Impact on Survival of the Level of HER2/neu Gene Amplification in Patients with HER2−Positive (HER2+) Advanced Breast Cancer (AdvBrCa) Treated with Trastuzumab (H).
2011 · G Gullo, D Bettio, et al. · Cancer Research
5153 POSTER Pre-operative Chemotherapy + Trastuzumab (T) for HER-2 Altered Locally-advanced (LA) Breast Cancer (HER+BC) in Pregnancy
2011 · F. Kelleher, G. Gullo, et al. · European Journal of Cancer
Docetaxel, carboplatin, and trastuzumab (TCH) preoperative induction treatment (IRx) in patients (pts) with HER2-positive breast cancer (BC).
2011 · C. F. Kelleher, F. Sclafani, et al. · Journal of Clinical Oncology
The level of HER2/neu gene amplification as predictive factor in patients with metastatic breast cancer treated with a trastuzumab-based therapy
2008 · G. Gullo, D. Bettio, et al. · European Journal of Cancer Supplements
Micrometastasis in sentinel (SLN) and non-sentinel lymph nodes of breast cancer: An update including clinico-pathologic impact and survival
2006 · G. Masci, L. Di Tommaso, et al. · Journal of Clinical Oncology
Works count: 22
Citation count: 56
H-index: 3
I10-index: 1
Year
Topic
Type